Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2011-03-29
2011-03-29
Spector, Lorraine (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S155100, C424S152100, C424S135100, C424S133100, C514S249000
Reexamination Certificate
active
07914785
ABSTRACT:
The present invention relates in a first aspect to a B-cell depleting anti-CD20 antibody or a CD20-binding antibody fragment thereof for the treatment of chronic fatigue syndrome and myalgic encephalomyelitis. In particular, the present invention relates to the use of anti-CD20 monoclonal antibodies or fragments thereof which are preferably humanized for the treatment of chronic fatigue syndrome/myalgic encephalomyelitis in a subject afflicted with said disease.
REFERENCES:
patent: 3773919 (1973-11-01), Boswell et al.
patent: 4816567 (1989-03-01), Cabilly
patent: 4861579 (1989-08-01), Meyer
patent: 5229275 (1993-07-01), Goroff
patent: 5545807 (1996-08-01), Surani et al.
patent: 5565332 (1996-10-01), Hoogenboom et al.
patent: 5567810 (1996-10-01), Weis et al.
patent: 5571894 (1996-11-01), Wels et al.
patent: 5587458 (1996-12-01), King et al.
patent: 5589369 (1996-12-01), Seidman et al.
patent: 5591669 (1997-01-01), Krimpenfort
patent: 5595721 (1997-01-01), Kaminski et al.
patent: 5641870 (1997-06-01), Rinderknecht
patent: 5677180 (1997-10-01), Robinson
patent: 5693780 (1997-12-01), Newman et al.
patent: 5721108 (1998-02-01), Robinson et al.
patent: 5736137 (1998-04-01), Anderson et al.
patent: 5776456 (1998-07-01), Anderson et al.
patent: 5843398 (1998-12-01), Kaminski et al.
patent: 5843439 (1998-12-01), Anderson et al.
patent: 5849898 (1998-12-01), Seed et al.
patent: 6015542 (2000-01-01), Kaminski et al.
patent: 6090365 (2000-07-01), Kaminski et al.
patent: 6120767 (2000-09-01), Robinson et al.
patent: 6171586 (2001-01-01), Lam et al.
patent: 6194551 (2001-02-01), Idusogie et al.
patent: 6224866 (2001-05-01), Barbera-Guillem
patent: 6242195 (2001-06-01), Idusogie et al.
patent: 6267958 (2001-07-01), Andya et al.
patent: 6287537 (2001-09-01), Kaminski et al.
patent: 6399061 (2002-06-01), Anderson et al.
patent: 6410391 (2002-06-01), Zelsacher
patent: 6455434 (2002-09-01), Binkerd et al.
patent: 6528624 (2003-03-01), Idusogie et al.
patent: 6538124 (2003-03-01), Idusogie et al.
patent: 6565827 (2003-05-01), Kaminski et al.
patent: 6652852 (2003-11-01), Robinson et al.
patent: 6682734 (2004-01-01), Anderson et al.
patent: 2002/0004587 (2002-01-01), Miller et al.
patent: 2002/0009427 (2002-01-01), Wolin
patent: 2002/0012665 (2002-01-01), Hanna
patent: 2002/0058029 (2002-05-01), Hanna
patent: 2002/0128488 (2002-09-01), Yamakawa
patent: 2002/0136719 (2002-09-01), Shenoy et al.
patent: 2002/0197255 (2002-12-01), Anderson et al.
patent: 2002/0197256 (2002-12-01), Grewal
patent: 2003/0029181 (2003-02-01), Terauchi
patent: 2003/0068664 (2003-04-01), Albitar et al.
patent: 2003/0082172 (2003-05-01), Anderson et al.
patent: 2003/0095963 (2003-05-01), Anderson et al.
patent: 2003/0103971 (2003-06-01), Hariharan
patent: 2003/0147885 (2003-08-01), Anderson et al.
patent: 2003/0157108 (2003-08-01), Presta
patent: 2003/0180292 (2003-09-01), Hanna et al.
patent: 2003/0185796 (2003-10-01), Wolin et al.
patent: 2003/0219818 (2003-11-01), Bohen et al.
patent: 0 330 191 (1988-02-01), None
patent: 0 332 865 (1988-03-01), None
patent: WO 93/11161 (1993-06-01), None
patent: WO 93/16185 (1993-08-01), None
patent: WO 95/03770 (1995-02-01), None
patent: WO 00/09160 (1998-08-01), None
patent: WO 98/35036 (1998-08-01), None
patent: WO 98/56418 (1998-12-01), None
patent: WO 98/58964 (1998-12-01), None
patent: WO 99/22764 (1999-05-01), None
patent: WO 99/51642 (1999-10-01), None
patent: WO 00/20864 (2000-04-01), None
patent: WO 00/27428 (2000-05-01), None
patent: WO 00/27433 (2000-05-01), None
patent: WO 00/42072 (2000-07-01), None
patent: WO 00/44788 (2000-08-01), None
patent: WO 00/67795 (2000-11-01), None
patent: WO 00/67796 (2000-11-01), None
patent: WO 01/03734 (2001-01-01), None
patent: WO 01/10460 (2001-02-01), None
patent: WO 01/10461 (2001-02-01), None
patent: WO 01/10462 (2001-02-01), None
patent: WO 01/13945 (2001-03-01), None
patent: WO 01/34194 (2001-05-01), None
patent: WO 01/74388 (2001-10-01), None
patent: WO 01/77342 (2001-10-01), None
patent: WO 01/80884 (2001-11-01), None
patent: WO 01/97858 (2001-12-01), None
patent: WO 02/04021 (2002-01-01), None
patent: WO 02/34790 (2002-05-01), None
patent: WO 02/079255 (2002-10-01), None
patent: WO 03/002607 (2003-01-01), None
patent: WO 03/049694 (2003-06-01), None
patent: WO 03/061694 (2003-07-01), None
patent: WO 03/068821 (2003-08-01), None
patent: WO 2004/035607 (2004-04-01), None
Center for Disease Control and Prevention, “Chronic Fatigue Syndrome: Causes” [online], last updated Oct. 15, 2010 [retrieved Nov. 1, 2010], Retrieved from internet<URL: http://www.cdc.gov/cfs/general/causes/index.html#>.
Nye, F., Letters to the editor: Chronic fatigue syndrome and myalgic encephalomyelitis: The 2007 guildelines from the National Institute of Clinical Excellence, J. Infection, 55:569-572, 2007.
Lundell et al., Clinical activity of folinic acid in patients with chronic fatigue syndrome, Arznelm.-Forsch./Drug Res. 56(6):399-404, 2006.
Lyall et al., A systematic review and critical evaluation of the immunology of chronic fatigue syndrome, J. Physchosomatic Res. 55:79-90, 2003.
Prins et al., Chronic fatigue syndrome, The Lancet, 376:346-355, Jan. 28, 2006.
Klimas, N., “Immunologic Abnormalities in Chronic Fatigue Syndrome”, Journal of Clinical Microbiolgy, vol. 28, No. 6, 1990, pp. 1403-1410.
Robertson, et al., “Lyphocyte Subset Differences in Patients with Chronic Fatigue Syndrome, Multiple Sclerosis and Major Depression”, Clinical and Expermimental Immuology, vol. 141, 2005, pp. 326-332.
Eurpoean search report for EP 08000006.0, filed Jan. 2, 2008.
Fluge Oystein
Mella Olav
Bergen Teknologieverforing AS
Kaufman Claire
Spector Lorraine
Whitham Curtis Christofferson & Cook PC
LandOfFree
B-cell depleting agents, like anti-CD20 antibodies or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with B-cell depleting agents, like anti-CD20 antibodies or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and B-cell depleting agents, like anti-CD20 antibodies or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2725957